Argo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB

First Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia

Argo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.

Argo Biopharma closed series A+ financing of over 40 milion US dollars led by CS Capital.

Argo Biopharma’s first siRNA drug approved for clinical study in China, the United States, and Australia.